AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data

AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate (ADC) IMGC936 fell short of safety and efficacy expectations in solid tumors, prompting AbbVie and its equal partner MacroGenics to walk away from the candidate.